Zacks Investment Research on MSN
Does Ironwood's bullish 2026 view signal greater Linzess adoption?
Ironwood Pharmaceuticals IRWD has been witnessing improved demand for its sole marketed product, Linzess (linaclotide), in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results